
## Francisco Vega

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/457670/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. Modern Pathology, 2022, 35, 306-318.	5.5	16
2	Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma. Modern Pathology, 2022, 35, 412-418.	5.5	4
3	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. Journal of Clinical Oncology, 2022, 40, 202-212.	1.6	34
4	Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (â‰ <b>®</b> 5 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncology, The, 2022, 23, 406-415.	10.7	22
5	Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies. Blood, 2022, 139, 951-951.	1.4	7
6	SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Advances, 2022, 6, 3286-3293.	5.2	3
7	Smoothened (SMO) regulates insulin-like growth factor 1 receptor (IGF1R) levels and protein kinase B (AKT) localization and signaling. Laboratory Investigation, 2022, 102, 401-410.	3.7	6
8	Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2022, 63, 1302-1313.	1.3	9
9	LMO2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage. Modern Pathology, 2022, 35, 1220-1226.	5.5	4
10	<scp>CD70</scp> is a potential target biomarker in peripheral T ell lymphomas. Histopathology, 2022, 81, 272-275.	2.9	3
11	CD2-negative lymphoma-associated T-cells: a potential mechanism of immune-evasion in diffuse large B-cell lymphoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 659-663.	2.8	2
12	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748.	7.2	1,023
13	ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment. Cancers, 2022, 14, 2939.	3.7	2
14	Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma. Haematologica, 2021, 106, 1714-1724.	3.5	30
15	Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of <scp>CD26</scp> â^' or <scp>CD7</scp> âr' <scp>CD4</scp> + Tâ€cells. Cytometry Part B - Clinical Cytometry, 2021, 100, 183-191.	1.5	15
16	MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma. Human Pathology, 2021, 108, 22-31.	2.0	6
17	Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. Leukemia and Lymphoma, 2021, 62, 1129-1135.	1.3	6
18	The uracil-DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID. NAR Cancer, 2021, 2, zcaa019.	3.1	10

#	Article	IF	CITATIONS
19	Targeted based therapy in nodal T-cell lymphomas. Leukemia, 2021, 35, 956-967.	7.2	5
20	CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood, 2021, 138, 1081-1085.	1.4	84
21	Unexpected Primary Extranodal Marginal Zone Lymphoma of Bone in Amputation and Arthroplasty Specimens. American Journal of Clinical Pathology, 2021, 156, 1038-1043.	0.7	0
22	Epstein–Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. Modern Pathology, 2021, 34, 2154-2167.	5.5	25
23	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. Modern Pathology, 2021, 34, 2183-2191.	5.5	7
24	BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified. Blood Cancer Journal, 2021, 11, 153.	6.2	1
25	Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors. Cancer Research, 2021, 81, 763-775.	0.9	13
26	Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases. Human Pathology, 2021, 118, 60-68.	2.0	4
27	SOHO State of the Art Updates and Next Questions:"SOHO State of the Art Updates and Next Questions: Pathology and Pathogenesis of Nodal Peripheral T-Cell Lymphomas. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	0
28	The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways. Cancer Research Communications, 2021, 1, 1-16.	1.7	7
29	lbrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial. Blood, 2021, 138, 3525-3525.	1.4	8
30	KSHV/HHV8-positive large B-cell lymphomas and associated diseases: a heterogeneous group of lymphoproliferative processes with significant clinicopathological overlap. Modern Pathology, 2020, 33, 18-28.	5.5	39
31	Recent BCR stimulation induces a negative autoregulatory loop via FBXO10 mediated degradation of HGAL. Leukemia, 2020, 34, 553-566.	7.2	10
32	Epstein–Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: a review. Pathology, 2020, 52, 40-52.	0.6	44
33	Comparison Between Integrated Genomic DNA/RNA Profiling and Fluorescence In Situ Hybridization in the Detection of MYC, BCL-2, and BCL-6 Gene Rearrangements in Large B-Cell Lymphomas. American Journal of Clinical Pathology, 2020, 153, 353-359.	0.7	4
34	Primary cutaneous Rosai-Dorfman disease; a case-based review of a diagnostically and therapeutically challenging rare variant. Annals of Diagnostic Pathology, 2020, 45, 151446.	1.3	12
35	Unusual Variants of Follicular Lymphoma. American Journal of Surgical Pathology, 2020, 44, 329-339.	3.7	11
36	American Registry of Pathology Expert Opinions: Recommendations for the diagnostic workup of mature T cell neoplasms. Annals of Diagnostic Pathology, 2020, 49, 151623.	1.3	8

#	Article	IF	CITATIONS
37	Pathology and Pathogenesis of T-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S89-S93.	0.4	3
38	Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: A single center analysis. Cancer Medicine, 2020, 9, 5051-5064.	2.8	6
39	A suggested immunohistochemical algorithm for the classification of T-cell lymphomas involving lymph nodes. Human Pathology, 2020, 102, 104-116.	2.0	11
40	Classic Hodgkin lymphoma and Castleman disease: an entity appears to be emerging. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 437-444.	2.8	7
41	Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers. Modern Pathology, 2020, 33, 2422-2436.	5.5	15
42	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma ( <scp>MCL</scp> ) ―outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patients. American Journal of Hematology, 2020, 95, 623-629.	4.1	54
43	Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not?. Blood, 2020, 135, 1299-1302.	1.4	8
44	A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). Blood, 2020, 136, 40-41.	1.4	15
45	Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma. Blood, 2020, 136, 41-42.	1.4	0
46	Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. Blood, 2020, 136, 27-28.	1.4	0
47	Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors - Comprehensive Analysis of 396 Patients. Blood, 2020, 136, 32-33.	1.4	2
48	Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome. Leukemia and Lymphoma, 2019, 60, 230-233.	1.3	18
49	Disseminated cutaneous immunoglobulin M macroglobulinosis associated with cryoglobulinemia and minimal residual disease of Waldenström macroglobulinemia. JAAD Case Reports, 2019, 5, 918-922.	0.8	3
50	LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL. Cancer Cell, 2019, 36, 237-249.e6.	16.8	50
51	Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. Cancer Discovery, 2019, 9, 944-961.	9.4	36
52	Longâ€ŧerm overall―and progressionâ€free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent nonâ€Hodgkin lymphoma. British Journal of Haematology, 2019, 185, 670-678.	2.5	7
53	A case of <scp>EBV</scp> â€associated blastic lymphoplasmacytic proliferation in an oesophageal ulcer with a selfâ€limiting course: overlapping lesion between <scp>EBV</scp> mucocutaneous ulcer and polymorphic lymphoplasmacytic disorder. Histopathology, 2019, 74, 964-966.	2.9	5
54	Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. American Journal of Hematology, 2019, 94, 585-596.	4.1	25

#	Article	IF	CITATIONS
55	CRISPR genome editing of murine hematopoietic stem cells to create Npm1-Alk causes ALK+ lymphoma after transplantation. Blood Advances, 2019, 3, 1788-1794.	5.2	5
56	Central Nervous System Involvement by Small Lymphocytic Lymphoma after a Myxoma-Related Embolic Event. Case Reports in Hematology, 2019, 2019, 1-6.	0.4	1
57	Prevalence, clinical characteristics and prognosis of EBVâ€positive follicular lymphoma. American Journal of Hematology, 2019, 94, E62-E64.	4.1	15
58	CD4+/CD8+ immunophenotype switching as a marker for intraocular and CNS involvement in mycosis fungoides. Leukemia and Lymphoma, 2019, 60, 1308-1311.	1.3	5
59	Adult T-cell leukemia/lymphoma can be indistinguishable from other more common T-cell lymphomas. The University of Miami experience with a large cohort of cases. Modern Pathology, 2018, 31, 1046-1063.	5.5	22
60	Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy. Leukemia and Lymphoma, 2018, 59, 2096-2104.	1.3	0
61	Epstein-Barr Virus–Positive Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue in the Posttransplant Setting. American Journal of Clinical Pathology, 2018, 149, 42-49.	0.7	11
62	Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. Leukemia Research, 2018, 64, 34-41.	0.8	41
63	Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. Modern Pathology, 2018, 31, 429-441.	5.5	17
64	Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. Journal of Clinical Oncology, 2018, 36, 3370-3380.	1.6	44
65	Intracytoplasmic azurophilic inclusions in prolymphocytes. International Journal of Hematology, 2018, 108, 565-565.	1.6	0
66	Splenic B-Cell Lymphomas with Diffuse Cyclin D1 Protein Expression and Increased Prolymphocytic Cells: A Previously Unrecognized Diagnostic Pitfall. Case Reports in Hematology, 2018, 2018, 1-9.	0.4	2
67	Smoothened stabilizes and protects TRAF6 from degradation: A novel non-canonical role of smoothened with implications in lymphoma biology. Cancer Letters, 2018, 436, 149-158.	7.2	10
68	Primary Intramedullary Spinal Cord Lymphoma Presenting as a Cervical Ring–Enhancing Lesion in an AIDS Patient. Open Forum Infectious Diseases, 2018, 5, ofy128.	0.9	4
69	Monotypic and IgH-rearranged lymphoplasmacytic cells restricted to the light zone of germinal centers: an early (in situ?) marginal zone lymphoma?. Annals of Hematology, 2018, 97, 1999-2000.	1.8	0
70	PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. Blood, 2018, 132, 2026-2039.	1.4	48
71	Target-Based Screening against elF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with <i>In Vivo</i> Antitumor Activity. Clinical Cancer Research, 2018, 24, 4256-4270.	7.0	41
72	CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. Cancer Cell, 2018, 33, 1111-1127.e5.	16.8	48

#	Article	IF	CITATIONS
73	Genetic Landscape of Ocular Adnexa Extranodal Marginal Zone Lymphoma. Blood, 2018, 132, 923-923.	1.4	Ο
74	CRISPR/Cas9 Generation of Npm1-Alk in Transplantable Murine Hematopoietic Stem Cells Accurately Models ALK-Positive Lymphoma in Recipients. Blood, 2018, 132, 779-779.	1.4	0
75	Characteristics and outcomes of lymphoblastic lymphoma – the University of Miami experience. Leukemia and Lymphoma, 2017, 58, 195-198.	1.3	0
76	Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study. Blood, 2017, 129, 324-332.	1.4	60
77	Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell–dependent cytotoxicity. Blood, 2017, 129, 2246-2256.	1.4	23
78	Hepatosplenic T-cell lymphoma associated with membranoproliferative glomerulonephritis. Leukemia and Lymphoma, 2017, 58, 2734-2737.	1.3	1
79	Clusters of paracortical plasmacytoid dendritic cells in lupus lymphadenitis. Blood, 2017, 129, 1884-1884.	1.4	1
80	Indolent <scp>ALK</scp> â€negative anaplastic largeâ€cell lymphoma, <i><scp>DUSP</scp>22</i> rearranged, with an unusual immunophenotype in a human immunodeficiency virus patient. Histopathology, 2017, 70, 1173-1175.	2.9	3
81	Epstein-Barr virus-positive follicular lymphoma. Modern Pathology, 2017, 30, 519-529.	5.5	44
82	Incidental brown adipose tissue in bone marrow biopsy. Blood, 2017, 130, 952-952.	1.4	5
83	Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences. Leukemia and Lymphoma, 2017, 58, 882-888.	1.3	34
84	A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy. International Journal of Molecular Sciences, 2017, 18, 1492.	4.1	10
85	Bone Marrow-Liver-Spleen Type of Large B-Cell Lymphoma Associated with Hemophagocytic Syndrome: A Rare Aggressive Extranodal Lymphoma. Case Reports in Hematology, 2017, 2017, 1-8.	0.4	2
86	Ten-year follow-up of pentostatin combined with cyclophosphamide, and rituximab in previously untreated indolent B-cell lymphoma Journal of Clinical Oncology, 2017, 35, e19040-e19040.	1.6	0
87	Prognostic Factors of Hepatosplenic T-cell Lymphoma. American Journal of Surgical Pathology, 2016, 40, 676-688.	3.7	65
88	Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?. American Journal of Hematology, 2016, 91, 277-282.	4.1	8
89	Deregulated expression of HDAC9 in B-cells promotes development of lymphoproliferative disease and lymphoma. DMM Disease Models and Mechanisms, 2016, 9, 1483-1495.	2.4	37
90	Primary Mediastinal Large B-Cell Lymphoma With Translocations Involving <i>BCL6</i> and <i>MYC</i> (Double-Hit Lymphoma). American Journal of Clinical Pathology, 2016, 145, 710-716.	0.7	5

#	Article	IF	CITATIONS
91	Active IKKβ promotes the stability of GLI1 oncogene in diffuse large B-cell lymphoma. Blood, 2016, 127, 605-615.	1.4	16
92	miR-181a negatively regulates NF-κB signaling and affects activated B-cell–like diffuse large B-cell lymphoma pathogenesis. Blood, 2016, 127, 2856-2866.	1.4	37
93	UNG protects B cells from AID-induced telomere loss. Journal of Experimental Medicine, 2016, 213, 2459-2472.	8.5	27
94	Early Detection of Myelodysplastic Syndromes: Maximizing the Utility of Automated Hematology. Blood, 2016, 128, 5527-5527.	1.4	1
95	Prognostic value of PET-CT in early stage Hodgkin Lymphoma (HL) using updated 5 point scoring system Journal of Clinical Oncology, 2016, 34, e19013-e19013.	1.6	0
96	Mutational Frequency in Hispanic Vs. Non-Hispanic Patients with Acute Myeloid Leukemia (AML). Blood, 2016, 128, 2796-2796.	1.4	0
97	The Novel Translocation t(4;15)(q31;q22) in AML Is Associated with a Proliferative Phenotype in the Presence of All-Trans Retinoic Acid (ATRA). Blood, 2016, 128, 1526-1526.	1.4	0
98	Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment. Blood, 2015, 125, 981-991.	1.4	52
99	Unusual immunophenotypic variant of large B-cell lymphoma associated with HHV-8 and EBV in an HIV positive patient. Human Pathology: Case Reports, 2015, 2, 49-54.	0.2	5
100	Shaping of the tumor microenvironment: Stromal cells and vessels. Seminars in Cancer Biology, 2015, 34, 3-13.	9.6	41
101	Hematolymphoid Neoplasms Associated With Rearrangements of PDGFRA, PDGFRB, and FGFR1. American Journal of Clinical Pathology, 2015, 144, 377-392.	0.7	55
102	Anaphylactic reaction to platelet transfusion as the initial symptom of an undiagnosed systemic mastocytosis: a case report and review of the literature. Journal of Medical Case Reports, 2014, 8, 389.	0.8	2
103	Blastic Plasmacytoid Dendritic Cell Neoplasm. American Journal of Dermatopathology, 2014, 36, 244-251.	0.6	12
104	Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14. Annals of Diagnostic Pathology, 2014, 18, 214-219.	1.3	15
105	Indolent peripheral T-cell lymphoma involving the gastrointestinal tract. Human Pathology, 2014, 45, 421-426.	2.0	37
106	Acquired B cell immunophenotype of follicular dendritic cells in a B cell-depleted lymph node after treatment with rituximab. Annals of Hematology, 2014, 93, 1947-1948.	1.8	3
107	De novo acute myeloid leukemia with monocytoid blasts and erythrophagocytosis. Clinical Case Reports (discontinued), 2014, 2, 333-335.	0.5	5
108	CD30-Negative Lymphomatoid Papulosis Type D in an Elderly Man. American Journal of Dermatopathology, 2014, 36, 190-192.	0.6	12

#	Article	IF	CITATIONS
109	Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype. Annals of Hematology, 2013, 92, 777-787.	1.8	17
110	Prospective phase <scp>II</scp> study of rituximab with alternating cycles of hyperâ€ <scp>CVAD</scp> and highâ€dose methotrexate with cytarabine for young patients with highâ€risk diffuse large <scp>B</scp> â€cell lymphoma. British Journal of Haematology, 2013, 163, 611-620.	2.5	23
111	Time to look for CD30 expression in diffuse large B-cell lymphomas, along the way to immunotherapy. Leukemia and Lymphoma, 2013, 54, 2341-2342.	1.3	3
112	Micro <scp>RNA</scp> signatures and treatment response in patients with advanced classical Hodgkin lymphoma. British Journal of Haematology, 2013, 162, 336-347.	2.5	39
113	Transcriptional Regulation of Serine/Threonine Protein Kinase (AKT) Genes by Glioma-associated Oncogene Homolog 1. Journal of Biological Chemistry, 2013, 288, 15390-15401.	3.4	37
114	Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment. Journal of Immunology, 2013, 190, 6681-6693.	0.8	77
115	Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphoma. Blood, 2013, 121, 4718-4728.	1.4	33
116	Pediatric subcutaneous panniculitis-like T-cell lymphoma with features of hemophagocytic syndrome. Pediatric Blood and Cancer, 2013, 60, 1916-1917.	1.5	11
117	Extranodal NK/T-cell Lymphoma, Nasal Type. American Journal of Surgical Pathology, 2013, 37, 14-23.	3.7	176
118	N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. Modern Pathology, 2012, 25, 231-236.	5.5	52
119	Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica, 2012, 97, 1080-1084.	3.5	56
120	Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood, 2012, 120, 347-355.	1.4	54
121	PI3KÎ' inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood, 2012, 119, 1897-1900.	1.4	143
122	Extracavitary/solid variant of primary effusion lymphoma. Annals of Diagnostic Pathology, 2012, 16, 441-446.	1.3	64
123	Aberrant Activation of the Hedgehog Signaling Pathway in Malignant Hematological Neoplasms. American Journal of Pathology, 2012, 180, 2-11.	3.8	67
124	Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. Journal of Hematology and Oncology, 2012, 5, 47.	17.0	27
125	Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma. Leukemia Research, 2012, 36, 1267-1273.	0.8	8
126	Highâ€grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with <i>BCL2</i> and/or <i>MYC</i> gene rearrangements and a poor prognosis. Histopathology, 2012, 61, 945-954.	2.9	44

#	Article	lF	CITATIONS
127	CD4/CD8 double-negative early-stage mycosis fungoides associated with primary cutaneous follicular center lymphoma. Journal of the American Academy of Dermatology, 2011, 65, 884-886.	1.2	7
128	Expression of serine 194–phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non–Hodgkin lymphomas. Human Pathology, 2011, 42, 1117-1124.	2.0	12
129	Glioma-associated oncogene homologue 3, a hedgehog transcription factor, is highly expressed in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Human Pathology, 2011, 42, 1643-1652.	2.0	18
130	Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma. Haematologica, 2011, 96, 871-880.	3.5	25
131	Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-l̂ºB–inducing kinase while activating both canonical and alternative nuclear factor-l̂ºB pathways. Blood, 2011, 117, 200-210.	1.4	63
132	Chronic Lymphocytic Leukemia With t(14;19)(q32;q13) Is Characterized by Atypical Morphologic and Immunophenotypic Features and Distinctive Genetic Features. American Journal of Clinical Pathology, 2011, 135, 686-696.	0.7	36
133	Follicular Dendritic Cell Sarcoma and Associated Myasthenia Gravis: True,True, Related?. Journal of Clinical Oncology, 2011, 29, e369-e371.	1.6	16
134	Side population of a murine mantle cell lymphoma model contains tumourâ€initiating cells responsible for lymphoma maintenance and dissemination. Journal of Cellular and Molecular Medicine, 2010, 14, 1532-1545.	3.6	19
135	V(D)J recombination and staggered DNA breaks: guilty again. Blood, 2010, 115, 2121-2122.	1.4	2
136	Angioimmunoblastic T-cell lymphoma in bone marrow: a morphologic and immunophenotypic study. Human Pathology, 2010, 41, 79-87.	2.0	30
137	Early-stage mycosis fungoides variants: case-based review. Annals of Diagnostic Pathology, 2010, 14, 369-385.	1.3	28
138	Sonic Hedgehog Signaling Pathway Is Activated in ALK-Positive Anaplastic Large Cell Lymphoma. Cancer Research, 2009, 69, 2550-2558.	0.9	84
139	Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-Cell lymphoma. Modern Pathology, 2009, 22, 1312-1320.	5.5	88
140	Nodular Lymphocyte Predominant Hodgkin Lymphoma With Clusters of LP Cells, Acute Inflammation, and Fibrosis. American Journal of Surgical Pathology, 2009, 33, 1725-1731.	3.7	10
141	<i>MYC</i> translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. British Journal of Haematology, 2008, 142, 36-44.	2.5	78
142	Splenic marginal zone lymphomas are characterized by loss of interstitial regions of chromosome 7q, 7q31.32 and 7q36.2 that include the protection of telomere 1 ( <i>POT1</i> ) and sonic hedgehog ( <i>SHH</i> ) genes. British Journal of Haematology, 2008, 142, 216-226.	2.5	36
143	Leukemia Cutis. American Journal of Clinical Pathology, 2008, 129, 130-142.	0.7	259
144	An Attractive Therapeutic Target, mTOR Pathway, in ALK+ Anaplastic Large Cell Lymphoma. Advances in Anatomic Pathology, 2008, 15, 105-112.	4.3	4

#	Article	IF	CITATIONS
145	t(8;13)-positive Bilineal Lymphomas. American Journal of Surgical Pathology, 2008, 32, 14-20.	3.7	48
146	Molecular Diagnostics of Lymphoid Malignancies. , 2008, , 655-674.		0
147	Expression of dicarbonyl/l-xylulose reductase (DCXR) in human skin and melanocytic lesions: morphological studies supporting cell adhesion function of DCXR. Journal of Cutaneous Pathology, 2007, 34, 535-542.	1.3	18
148	Tissue-Specific Function of Lymph Node Fibroblastic Reticulum Cells. Pathobiology, 2006, 73, 71-81.	3.8	23
149	Atypical NK-cell Proliferation of the Gastrointestinal Tract in a Patient With Antigliadin Antibodies but not Celiac Disease. American Journal of Surgical Pathology, 2006, 30, 539-544.	3.7	39
150	Activation of Mammalian Target of Rapamycin Signaling Pathway Contributes to Tumor Cell Survival in Anaplastic Lymphoma Kinase–Positive Anaplastic Large Cell Lymphoma. Cancer Research, 2006, 66, 6589-6597.	0.9	187
151	Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Modern Pathology, 2005, 18, 806-815.	5.5	322
152	Extranodal lymphomas of the head and neck. Annals of Diagnostic Pathology, 2005, 9, 340-350.	1.3	150
153	Phenotypic Modulation of the Stromal Reticular Network in Normal and Neoplastic Lymph Nodes. American Journal of Pathology, 2003, 163, 165-174.	3.8	49
154	Chromosomal Translocations Involved in Non-Hodgkin Lymphomas. Archives of Pathology and Laboratory Medicine, 2003, 127, 1148-1160.	2.5	71
155	Precursor T-Cell Acute Lymphoblastic Leukemia in Adults. American Journal of Clinical Pathology, 2002, 117, 252-258.	0.7	16
156	Peripheral T-Cell Lymphoma Arising in the Liver. American Journal of Clinical Pathology, 2002, 118, 574-581.	0.7	25
157	Real-Time t(14;18)(q32;q21) PCR Assay Combined with High-Resolution Capillary Electrophoresis: A Novel and Rapid Approach that Allows Accurate Quantitation and Size Determination of bcl-2/JH Fusion Sequences. Modern Pathology, 2002, 15, 448-453.	5.5	16
158	CD4â^' CD8â^' `Double-Negative' Cutaneous T-Cell Lymphomas Share Common Histologic Features and an Aggressive Clinical Course. American Journal of Surgical Pathology, 2002, 26, 225-231.	3.7	63
159	Epstein–Barr Virus-Positive B-Cell Lymphoproliferative Disorders Arising in Immunodeficient Patients Previously Treated With Fludarabine for Low-Grade B-Cell Neoplasms. American Journal of Surgical Pathology, 2002, 26, 630-636.	3.7	91
160	Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood, 2002, 100, 3369-3373.	1.4	133
161	Chromosomal translocations and their role in the pathogenesis of non-Hodgkin's lymphomas. Pathology, 2002, 34, 397-409.	0.6	7
162	The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B-cell tumours. British Journal of Haematology, 2002, 117, 569-576.	2.5	38

#	Article	IF	CITATIONS
163	Marginal-Zone B-Cell Lymphoma of Extranodal Mucosa-Associated Lymphoid Tissue Type: Molecular Genetics Provides New Insights into Pathogenesis. Advances in Anatomic Pathology, 2001, 8, 313-326.	4.3	22
164	A Novel Four-Color PCR Assay to Assess T-Cell Receptor Gamma Gene Rearrangements in Lymphoproliferative Lesions. American Journal of Clinical Pathology, 2001, 116, 17-24.	0.7	83
165	Hepatosplenic gamma/delta T-Cell Lymphoma in Bone Marrow. American Journal of Clinical Pathology, 2001, 116, 410-419.	0.7	107
166	Extramedullary hematopoiesis in juvenile polyposis coli. Gastrointestinal Endoscopy, 2000, 51, 330.	1.0	1